Original Investigation

Nutritional Support and Outcomes in Malnourished Medical Inpatients A Systematic Review and Meta-analysis

Martina R. Bally, MD; Prisca Z. Blaser Yildirim, MD; Lisa Bounoure, PhD; Viktoria L. Gloy, PhD; Beat Mueller, MD; Matthias Briel, MD, MSc; Philipp Schuetz, MD, MPH

IMPORTANCE During acute illness, nutritional therapy is widely used for medical inpatients with malnutrition or at risk for malnutrition. Yet, to our knowledge, no comprehensive trial has demonstrated that this approach is effective and beneficial for patients.

OBJECTIVE To assess the effects of nutritional support on outcomes of medical inpatients with malnutrition or at risk for malnutrition in a systematic review of randomized clinical trials (RCTs).

DATA SOURCES The Cochrane Library, MEDLINE, and EMBASE. The study dates were October 5, 1982, to April 30, 2014, in various (mostly European) countries. The dates of our analysis were March 10, 2015, to September 16, 2015.

STUDY SELECTION Based on a prespecified Cochrane protocol, we systematically searched RCTs investigating the effects of nutritional support (including counseling and oral and enteral feeding) in medical inpatients compared with a control group.

DATA EXTRACTION Two reviewers extracted data on study characteristics, methods, and outcomes. Disagreement was resolved by consensus.

MAIN OUTCOMES AND MEASURES The primary study outcome was mortality. Secondary outcomes included hospital-acquired infections, nonelective readmissions, functional outcome, length of hospital stay, daily caloric and protein intake, and weight change.

RESULTS We included 22 RCTs with a total of 3736 participants. Heterogeneity across RCTs was high, with overall low study quality and mostly unclear risk of bias. Intervention group patients significantly increased their weight (mean difference, 0.72 kg; 95% Cl, 0.23-1.21 kg), caloric intake (mean difference, 397 kcal; 95% Cl, 279-515 kcal), and protein intake (mean difference, 20.0 g/d; 95% Cl, 12.5-27.1 g/d) compared with control group patients. No differences between intervention group patients and control group patients were found with respect to mortality (9.8% vs 10.3%; odds ratio [OR], 0.96; 95% Cl, 0.72-1.27), hospital-acquired infections (overall, 6.0% vs 7.6%; OR, 0.75; 95% Cl, 0.50-1.11), functional outcome (mean Barthel index difference, 0.33 point; 95% Cl, -0.88 to 1.55 points), or length of hospital stay (mean difference, -0.42 days; 95% Cl, -1.09 to 0.24 days). Nonelective readmissions were significantly decreased by the intervention (20.5% vs 29.6%; risk ratio, 0.71; 95% Cl, 0.57-0.87).

CONCLUSIONS AND RELEVANCE In medical inpatients, nutritional support increases caloric and protein intake and body weight. However, there is little effect on clinical outcomes overall except for nonelective readmissions. High-quality RCTs are needed to fill this gap.

JAMA Intern Med. doi:10.1001/jamainternmed.2015.6587 Published online December 21, 2015. Invited Commentary

 Supplemental content at iamainternalmedicine.com

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Philipp Schuetz, MD, MPH, University Department of Medicine, Clinic for Endocrinology/Metabolism/ Clinical Nutrition, Kantonsspital Aarau, Tellstrasse, CH-5001 Aarau, Switzerland (schuetzph@gmail.com). alnutrition is common in hospitalized patients and is associated with detrimental metabolic consequences such as muscle wasting.^{1,2} Furthermore, malnutrition per se is associated with higher mortality and morbidity, increased infections, and prolonged length of hospital stay.³⁻⁵ This evidence explains the current clinical approach of providing nutritional support early as a strategy to treat malnutrition and its associated adverse outcomes.⁶

Recent high-quality, large-scale randomized clinical trials (RCTs) from critical care have challenged the approach of using nutritional therapy in the acute phase of illness in unselected patients.⁷ Deleterious effects of aggressive overfeeding were found in one large trial,⁸ and no benefit of enteral feeding over permissive underfeeding was found in another recent trial.⁹ Furthermore, the provision of parenteral nutrition to critically ill adults compared with standard care did not reduce mortality in an additional critical care trial.¹⁰ Given these results from critical care, the approach of using nutritional therapy in the acute phase of illness in medical inpatients with malnutrition or at risk for malnutrition needs to be challenged.

To our knowledge, no comprehensive trial or metaanalysis has investigated clinical benefit or harm associated with nutritional support in the medical inpatient population. Available meta-analyses focus on different study questions and patient populations, including enteral nutrition in critical care or perioperative patients,¹¹ protein and energy supplementation in the elderly,¹² nutritional support in liver disease,¹³ and nutritional supplementation after hip fracture in older individuals.¹⁴ Therefore, whether the use of nutritional therapy in medical inpatients has beneficial effects on outcomes such as mortality, hospital-acquired infections, nonelective readmissions, and functional outcome remains unclear.

To fill this knowledge gap, we conducted a comprehensive systematic review and meta-analysis of RCTs. We assessed the effects of nutritional support (oral or enteral) on outcomes in medical inpatients with malnutrition or at risk for malnutrition.

Methods

Eligibility Criteria

A previously published Cochrane protocol outlines our study methods.¹⁵ We included RCTs and quasi-RCTs that randomized noncritically ill medical inpatients with malnutrition or at risk for malnutrition to a nutritional therapy intervention or a control group.

We included RCTs that established risk for malnutrition based on body mass index, the presence of a medical condition strongly associated with malnutrition occurring during hospital stay, or the use of a nutritional assessment or screening tool (eg, Subjective Global Assessment, Malnutrition Universal Screening Tool, or Nutritional Risk Screening). Medical inpatients were defined as patients hospitalized in medical wards of acute care institutions, including geriatrics, gastroenterology, cardiology, pneumology, general internal medicine, infectious diseases, nephrology, and oncology.

Trials focusing on patients hospitalized in critical care wards or residing in nursing homes or long-term facilities, as well as outpatients, were not eligible for this analysis. In addition, trials focusing on surgical patients were also not eligible except for those reporting the results of mixed medical and surgical patient populations when the medical population was not reported separately. We also excluded trials focusing on patients with pancreatitis because of important differences in the nutritional concept of this disease compared with other acute medical illnesses (ie, withholding oral or enteral nutrition until days 3-5 is recommended in mild and moderate forms of acute pancreatitis).¹⁶

Types of Interventions

We included trials with interventions consisting of any type of nutritional support except for parenteral nutrition. For the comparator groups, we defined the following types of interventions: (1) dietary advice (changes in the organization of nutritional care [eg, support of dieticians or health care assistants, training in nutritional care for medical personnel, implementation of nutritional care pathways or protocols, and feeding assistance]), (2) food fortification (snacks between meals and increased caloric and protein intake), (3) oral feeding in addition to meals (any type of oral nutritional supplement), and (4) enteral feeding (any type of total or partial enteral [tube] feeding). In our primary analysis, we included any of the above nutritional strategies or any combination of them. There was no restriction regarding the minimum duration of the intervention.

We applied no restrictions with respect to control group treatments. We defined the following comparator groups: (1) no support, (2) usual care (possibly providing dietary advice or oral nutritional supplement), and (3) placebo treatment.

Outcomes

The primary study outcome was all-cause mortality, defined as death from any cause and measured at hospital discharge or at follow-up (up to 4-6 months after randomization). Secondary outcomes during follow-up included the following: hospital-acquired infections (with a new infection diagnosis after study inclusion until hospital discharge or at follow-up), nonelective readmissions (defined as any hospital or emergency department visit until follow-up), functional outcome (assessed by the Barthel index as an absolute measure at followup), length of hospital stay (defined as the time from hospital admission or randomization to discharge), and adverse events (defined based on the definition used in the original RCT). Other metabolic outcomes included body weight change (in kilograms), measured from study inclusion until hospital discharge or at follow-up, and the mean daily caloric intake (in kilocalories) and daily protein intake (in grams) during the intervention period. We also gathered information about adherence to the nutritional intervention and the study protocol.

Search Strategy

We searched 3 electronic databases, including the Cochrane Library, MEDLINE, and EMBASE, from the inception of each database to December 11, 2014. Search terms included extensive controlled vocabulary and Medical Subject Headings for (*RCTs*) AND (*malnutrition*) AND (*adults*) AND (*nutritional therapy*). We reviewed bibliographies of review articles and eligible trials and searched the clinicaltrials.gov registry for ongoing or unpublished trials. We also contacted experts working in the field of malnutrition to identify additional or unpublished trials.

Study Selection

Two reviewers (M.R.B. and P.Z.B.Y.) independently screened titles and abstracts of articles and full texts of any title or abstract deemed potentially eligible by either reviewer. We resolved any discrepancies through consensus or recourse to a third reviewer (P.S.).

Risk-of-Bias Assessment of Individual Studies

As recommended by the Cochrane Collaboration, 2 reviewers (M.R.B. and L.B.) independently assessed the risk of bias associated with individual RCTs.¹⁷ We used the following criteria: (1) random sequence generation (selection bias); (2) randomization concealment (selection bias); (3) blinding (performance bias and detection bias), separated for blinding of participants and personnel, and blinding of outcome assessment; (4) incomplete outcome data (attrition bias); (5) selective reporting (reporting bias); and (6) other bias. Furthermore, the quality of outcomes was assessed according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method.¹⁸

Data Extraction

For studies that fulfilled inclusion criteria, 2 reviewers (M.R.B. and P.Z.B.Y.) independently abstracted key participant and intervention characteristics and reported data on efficacy outcomes using a standardized data extraction template. Any disagreements were resolved by discussion or by consulting a third reviewer (P.S.). Continuous outcomes were most often reported as the absolute mean change from baseline, which we used directly to pool data. The absolute mean change was calculated in case continuous data were reported as preintervention and postintervention measures or percentage change. If standard deviations were missing and we did not receive information from study authors, we assumed missing standard deviations to be the mean (SD) of those studies in which this information was reported. We investigated the effect of this assumption by sensitivity analysis.

We maximized the yield of information by collating all the available data in the event of multiple publications, companion documents, or multiple reports and used the most complete data set aggregated across all available publications of an RCT. In case of doubt, we gave priority to the publication reporting the longest follow-up.

Data Synthesis and Analysis

We expressed dichotomous data as odds ratios (ORs) or risk ratios with 95% CIs. We expressed continuous data as the mean differences with 95% CIs. Data were pooled using a randomeffects model.

Assessment of Heterogeneity and Publication Bias

In the event of substantial clinical, methodological, or statistical heterogeneity, we did not pool the effect estimates in a meta-analysis. We identified heterogeneity (inconsistency) through visual inspection of the forest plots and by using a standard χ^2 test with a significance level of $\alpha = .10$. In view of the low power of this test, we also considered the I^2 statistic, which quantifies inconsistency across studies, to assess the effect of heterogeneity on the meta-analysis.¹⁹ An I^2 statistic of 50% or more indicates a considerable level of heterogeneity.

We used visual inspection of funnel plots to assess publication bias. Owing to several possible explanations for funnel plot asymmetry, we interpreted these results cautiously.²⁰

We also performed a predefined subgroup analysis stratified by degree of malnutrition (ie, established malnutrition vs risk for malnutrition). Furthermore, we performed additional exploratory subgroup analyses investigating adherence to the study protocol, mortality risk in control group patients (<10% vs \geq 10%), and route of feeding (oral vs enteral).

Results

Systematic Search

Our systematic search identified 4393 titles and abstracts of potentially eligible studies from electronic databases and one additional record through contact with experts. After removal of duplicates, 2673 records were screened, and 44 full texts were assessed for eligibility. Of these results, 22 RCTs (with a total of 3736 patients) were included in the final meta-analysis. A flowchart is shown in **Figure 1**.


Most of the included RCTs were single-center studies and involved heterogeneous adult medical or mixed medical and surgical inpatients. The study dates were October 5, 1982, to April 30, 2014, in various (mostly European) countries. The dates of our analysis were March 10, 2015, to September 16, 2015. Interventions were mainly oral feeding strategies, with 2 trials also providing enteral feeding to the intervention group. Nutritional counseling was part of the intervention in most studies. Control group patients were mostly treated based on usual care. Five trials used a placebo-controlled intervention. Additional characteristics of the included RCTs are summarized in **Table 1**.

Risk-of-Bias Assessment

We investigated performance bias, detection bias, and attrition bias separately for objective and subjective outcome measures in each individual trial as recommended by the Cochrane Collaboration (eAppendix in the Supplement). Appropriate random sequence generation and randomization concealment were used in less than half of all trials, with many trials not reporting procedural details. There was a low or unclear risk of bias in most trials except for performance bias because masking of participants and personnel to the nutritional interventions was not done in most studies. Also, attrition bias was high or unclear because of incomplete outcome reporting in many studies. The quality of the evidence according to the GRADE method to assess the effects of nutritional support on mortality was low and was low to very low for all other outcomes.

jamainternalmedicine.com

Research Original Investigation



ICU indicates intensive care unit.

Primary Outcome

Table 2 summarizes outcomes in the overall population and in subgroups. For the primary end point, 14 studies reported all-cause mortality, ranging from 4% to 52% in the various RCTs. In the overall analysis, death occurred in 9.8% (133 of 1361) of intervention group patients compared with 10.3% (144 of 1395) of control group patients (OR, 0.96; 95% CI, 0.72-1.27). We found low heterogeneity among trials ($I^2 = 8\%$, P = .37) (Figure 2). We then stratified the results based on the type of intervention. There was no significant association between nutritional therapy and mortality in any of the subgroups based on the type of nutritional therapy. In the 4 trials comparing oral feeding with placebo, the effect estimates tended to be worse for the nutritional intervention (OR, 1.52; 95% CI, 0.96-2.39). In the 3 trials comparing oral nutrition alone with usual care, the effect estimates tended to indicate benefit from nutritional therapy (OR, 0.61; 95% CI, 0.35-1.05).

Secondary Outcomes

Thirteen RCTs reported the length of hospital stay, and 6 RCTs reported nonelective readmissions. The readmission rate was significantly lower in intervention group patients compared with control group patients (20.5% vs 29.6%; risk ratio, 0.71; 95% CI, 0.57-0.87), with overall low heterogeneity among trials ($I^2 = 0\%$) (**Figure 3**). Overall, the length of hospital stay was not significantly shorter in intervention group patients com-

pared with control group patients (13.0 vs 10.8 days; difference, -0.42 days; 95% CI, -1.09 to 0.24 day). This finding was also true for most individual trials, with overall low heterogeneity among trials ($I^2 = 0\%$) (Table 2 and eAppendix in the Supplement).

No significant effect was found for infections in any individual trial or in the overall analysis (overall, 6.0% vs 7.6%; OR, 0.75; 95% CI, 0.50-1.11), with low heterogeneity $(I^2 = 0\%)$ (eAppendix in the Supplement). Four RCTs reported functional outcome with measurement of the Barthel index at follow-up. There was no significant difference in the Barthel index between intervention group patients and control group patients in the overall analysis (mean Barthel index difference, 0.33 points; 95% CI, -0.88 to 1.55 points). Heterogeneity among these trials was high $(I^2 = 78\%)$. Stratification of the 4 RCTs by comparison category explained the identified heterogeneity, and there was no evidence of any difference between groups except for one RCT comparing oral feeding alone vs no support. In that RCT, a significant difference in the Barthel index of 4 points (95% CI, 1.69-6.31 points) was found, suggesting better functional outcome in patients with oral feeding. Test for interaction indicated a statistically significant result (P = .004).

For adverse outcomes associated with nutritional therapy, trials showed high heterogeneity. Therefore, we did not further include adverse outcomes in the meta-analysis.

Population Country Sample Size Congestive heart failure Sweden 21 Bg Alcoholic liver disease Chile 36 Hospitalized adults Sweden 21 E65 yat nutritional risk Israel 259 Hospitalized adults Israel 259 Odder patients Belgium 80 Otder patients Belgium 80 D04 Acutely ill elderly inpatients Belgium 80 D12 Older patients England 25 D13 Older patients England 54 D14 Elderly medical England 54 D15 Older patients England 54 D15 Older patients England 54 Autologer England 54 55 Autologer England 54 54 D15 Inderly matute England 54 Patients Mustralia 54 54 D15 Hosp	Sample Size 21 21 36 36 36 36 36 259 80 80 252 252 592 592 592 592 593 6 143 54 86 86 nds add 210 nds 220	n n ng ng ents	Control Group Normal hospital food and 1:10 diluted placeboversion of ONS Standard diet Routine care on request Oral placebo (60 kcal) Standard hospital food, no supplements Usual care U. Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitamins A (8000 U), and C (500 mg) during 1 mo D. Nutrasweet glucose drink and placebo capsules drink and capsules drink and placebo capsules Ormal hospital diet Normal hospital diet
Congestive heart failure Sweden 21 89 Alcoholic liver disease Chile 36 Hospitalized adults Israel 259 265 yat nutritional risk Belgium 80 Hospitalized acutely ill England 445 Older patients Belgium 80 Patients z75 yand at risk Belgium 80 Older patients Belgium 80 Older patients England 25 D11 Older patients England 592 D12 Older patients England 592 D13 Older patients England 54 Patients England 54 54 D14 Patients England 54 Patients England 54 54 Patients Hospitalized patients 54 54 Acutely III older England 54 54 Patients Hospitalized patients 54 54 Inpatients Hospita	21 36 259 80 80 80 592 25 25 25 25 25 25 86 86 86 86 86 81 86 0nd 210	n al/d, ng ents	Normal hospital food and 1:10 diluted placebo version of ONS Standard diet Routine care on request Oral placebo (60 kcal) Standard hospital food, no supplements Standard hospital food, no supplements Usual care Usual care 1. Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitamins A (8000 U), B ₁ (15 mg), B ₂ (15 mg), B ₆ (10 mg), and C (500 mg) during 1 mo 2. Nutrasweet glucose drink and placebo capsules during 1 mo 2. Nutrasweet glucose drink and placebo capsules during 1 mo Standard hospital diet Normal hospital diet
89 Alcoholic liver disease Chile 36 81 Hospitalized adults 5rael 259 85 yat nutritional risk Ergland 445 9004 Hospitalized acutely ill England 445 9004 Acutely ill elderly inpatients England 592 9012 Eldery medical England 592 912 Older patients England 54 912 Older patients, depression Australia 143 913 Older patients, depression Australia 54 914 England 54 54 915 Elderly malnourished England 54 916 Elderly malnourished England 54 913 Older patients England 54 914 Hospitalized patients Belgium 86 914 Hospital-admitted Hospital-admitted 81 915 Hospital-admitted Netherlands 29 91 Hospital-admitted Netherlands 29 92 Hospital-admitted Netherlands 29 93 Hospital-admitted Netherlands 29 93 Hospital-adulted Netherlands	36 36 259 80 80 592 25 25 25 54 86 86 86 86 86 86 86 86 0nd 210 0nd 29	product at/d, ng ents	Standard diet Routine care on request Oral placebo (60 kcal) Standard hospital food, no supplements Usual care Usual care 1. Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitanins A (800 U), B ₁ (15 mg), B ₂ (15 mg), B ₆ (10 mg), and c (500 mg) during 1 mo 2. Nutrasweet glucose drink and placebo capsules during 1 mo 2. Nutrasweet dication only on request Normal hospital diet
Hospitalized adultsErael259265 y at nutritional riskEngland445Hospitalized acutely illEngland445Older patientsSand at riskBelgium80for undernutritionEngland592Elderly medicalEngland592IppatientsEngland592Elderly medicalEngland54patientsEngland54patientsEngland54patientsEngland54patientsEngland54patientsEngland86inpatientsEngland86inpatientsEngland86inpatientsEngland86inpatientsEngland81in acute aged careBenmark210in acute aged careNetherlands29elukemiaHospitalized batientsEngland381individualsEnglandFinanco381individualsEnglandFinanco36ensentsEnglandFinanco36individualsEnglandFinanco36isikPatients at nutritionalFinanco36isikPatients at nutritionalFinanco33isikPatients at nutritionalFinanco33isikPatients at nutritionalFinanco33isikPatients at nutritionalFinanco33isikPatients at nutritionalFinanco33isikPatients at nutrition	259 445 80 80 592 25 25 25 25 54 86 86 86 86 86 86 86 86 87 210 http://www.com/action/	n al/d, ents	Routine care on request Oral placebo (60 kcal) Standard hospital food, no supplements Usual care Usual care 1. Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitanins A (8000 U), B ₁ (15 mg), B ₂ (15 mg), B ₆ (10 mg), and C (500 mg) during 1 mo 2. Nutrasweet glucose drink and placebo capsules during 1 mo 2. Nutrasweet glucose drink and placebo capsules Individual modification only on request Normal hospital diet Standard hospital diet
Hospitalized acutedy ill England 445 older patients ender patients 80 for undernutrition 80 D04 Acutely ill elderly inpatients 592 Elderly medical England 25 inpatients Fnyland 25 D12 Older patients, depression Australia 143 Elderly malnourished England 54 patients England 54 Acutely ill older England 54 patients England 54 Acutely ill older England 54 inpatients England 54 Acutely ill older England 54 inpatients England 36 Hospital-admitted the 210 malnourished elderly Netherlands 210 Patients with acute Germany 29 Patients with acute England 36 Manourished elderly Netherlands 36 Patients with acute Switzerland 36 Patients at nutritional Fnance 16 fisk Patients at nutritional 54	445 80 592 25 25 25 25 25 54 54 86 86 86 81 80 0nd 210	ng ents	Oral placebo (60 kcal) Standard hospital food, no supplements Usual care Usual care 1. Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitamins A (8000 U), B1 (15 mg), B ₂ (15 mg), B ₃ (50 mg), B ₆ (10 mg), and C (500 mg) during 1 mo and C (500 mg) during 1 mo during 1 mo Undividual modification only on request Normal hospital diet Standard hospital diet
Patients 275 y and at risk Belgium 80 for undernutrition 592 004 Acutely ill elderly inpatients 592 Elderly medical England 592 012 Older patients, depression Australia 143 012 Older patients, depression Australia 143 012 Older patients, depression Australia 143 Patients England 54 inpatients England 54 acutely ill older England 86 inpatients England 86 acutely ill older England 86 inpatients England 81 acutely ill older England 81 in acute aged care Matherlands 210 malnourished elderly Netherlands 29 elukemia Hospitalized elderly Figland 381 elukemia Hospitalized elderly England 36 enstrow transplantation Switzerland 36 erisk Patients at nutritional 54 erisk Patients at nutritional 54	80 592 25 25 54 54 86 86 86 86 86 86 86 86 7 210	al/d, ng ents	Standard hospital food, no supplements Usual care U. Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitamins A (8000 U), B1, (15 mg), B2, (15 mg), B3, (50 mg), B6, (10 mg), and C (500 mg) during 1 mo 2. Nutrasweet glucose drink and placebo capsules during 1 mo 2. Nutrasweet glucose drink and placebo capsules during 1 mo Standard hospital diet Standard hospital diet
004 Acutely ill elderly inpatients 592 Elderly medical England 59 012 Older patients, depression Australia 143 013 Elderly malnourished England 54 patients England 54 Patients England 54 Acutely ill older England 54 Patients England 86 Inpatients England 86 Patients Denmark 81 in acute aged care Netherlands 210 Patients with acute Germany 29 eukemia Netherlands 29 eukemia Netherlands 29 eukemia Mutologous bone 381 endrologous bone Switzerland 36 for solid tumors Switzerland 36 for solid tumors Tisk 33 for solid tumors France 16 for solid tumors Tisk 33	592 25 25 25 25 54 54 86 86 86 86 86 81 87 210 0nd 220	ents	Usual care Usual care 1. Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitamins A (8000 U), B, (15 mg), B ₂ (15 mg), B ₆ (10 mg), and C (500 mg) during 1, mo and C (500 mg) during 1 mo 2. Nutrasweet glucose drink and placebo capsules during 1 mo Individual modification only on request Normal hospital diet Standard hospital diet
Elderly medicalEngland25012Older patients, depressionAustralia143Elderly malnourishedEngland54patientsEngland54Acutely ill olderEngland54inpatientsEngland54Acutely ill olderEngland21inpatientsDenmark81in acute aged careNetherlands212Hospitalized patientsNetherlands292Patients with acuteGermany294Hospitalized elderlyEngland3816Autologous boneSwitzerland367Autologous boneSwitzerland369Patients at nutritionalFrance169Patients at nutritionalCanada3315kPatients at nutritionalCanada3315kPatients at nutritionalCanada3315kPatients at nutritionalCanada3315kPatients at nutritionalCanada3315kPatients at nutritionalCanada3315kPatients at nutritionalCanada33	25 143 54 86 81 81 81 29	ng ents	 Nutrasweet (Nutrasweet Company) glucose drink and capsules containing vitamins A (8000 U), B, (15 mg), B₂ (15 mg), B₃ (50 mg), B₆ (10 mg), and C (500 mg) during 1 mo Nutrasweet glucose drink and placebo capsules during 1 mo Individual modification only on request Normal hospital diet Standard hospital diet
⁸ 2012 Older patients, depression Australia 143 Elderly malnourished England 54 patients England 54 Acutely ill older England 54 Hospitalized patients England 86 Inpatients England 86 Hospitalized patients Denmark 81 In acute aged care the 210 In acute aged care the 210 malnourished elderly Netherlands 29 leukemia Hospitalized elderly Renany 29 errs Hospitalized elderly England 381 individuals England 36 outologous bone Switzerland 36 for solid tumors France 16 for solid tumors France <td< td=""><td>143 54 86 81 81 210 29</td><td>pplements cal/d</td><td>Individual modification only on request Normal hospital diet Standard hospital diet</td></td<>	143 54 86 81 81 210 29	pplements cal/d	Individual modification only on request Normal hospital diet Standard hospital diet
Elderly malnourished England 54 patients Acutely III older England 54 Acutely III older England 86 Inpatients England 86 Hospitalized patients Denmark 81 In acute aged care the 210 malnourished elderly Netherlands 29 etulkemia England 381 etulkemia England 381 urst Hotogous bone Switzerland 36 0.4 Patients at nutritional France 16 0.4 Patients at nutritional France 16 1.36 Patients at nutritional Canada 33	54 86 81 210 1ds 229	cal/d	Normal hospital diet Standard hospital diet
Acutely ill older England 86 inpatients Hospitalized patients 81 in acute aged care Denmark 81 in acute aged care 210 210 malnourished elderly Netherlands 29 Patients with acute Germany 29 eukemia England 381 erts Hospitalized elderly England 381 erts Autologous bone Switzerland 36 0.4 Patients at nutritional France 16 of Patients at nutritional Canada 33	86 81 81 nds 210	cal/d	Standard hospital diet
Hospitalized patients Denmark 81 in acute aged care bin acute aged care 81 in acute aged care the spital-admitted 210 malnourished elderly Netherlands 29 Patients with acute Germany 29 eukemia England 381 erts Hotogous bone Switzerland 36 , ³⁶ Autologous bone Switzerland 36 for solid tumors Switzerland 76 36 004 Patients at nutritional France 16 risk Patients at nutritional Canada 33	81 210 29		
1, ³² Hospital-admitted the 210 malnourished elderly Netherlands 29 Patients with acute Germany 29 eukemia Germany 29 envicenta Germany 381 envicenta England 381 1, ³⁶ Autologous bone Switzerland 36 marrow transplantation Switzerland 36 for solid tumors Switzerland 16 old4 Patients at nutritional France 16 erger Patients at nutritional Canada 33 risk risk 33 33	210 29		Standard hospital diet
Patients with acute Germany 29 leukemia 29 erukemia Hospitalized elderly England 381 erts individuals Switzerland 36 L ³⁶ Autologous bone Switzerland 36 narrow transplantation Switzerland 36 004 Patients at nutritional France 16 nerger Patients at nutritional Canada 33	29	additional servings of an ONS, of vitamin D ₃ , and 500 mg	Usual care
Hospitalized elderly England 381 individuals 83 Autologous bone 5witzerland 36 marrow transplantation 5 for solid tumors 16 Patients at nutritional France 16 risk 33 risk		aily visits by the dietician,	Menus of free choice, no nutritional education
Autologous boneSwitzerland36marrow transplantationfor solid tumorsfor solid tumorsPatients at nutritionalFrancePatients at nutritionalCanada33riskriskrisk	381		Normal hospital food
Patients at nutritional France 16 risk Patients at nutritional Canada 33 risk			2 U of ONS providing 200 mL each with 300 kcal and 12 g of protein
Patients at nutritional Canada 33 risk			Standard hospital breakfast
	33		Standard food, 29 kcal/kg/d
, ³⁹ Malnourished elderly United 400 patients States			Usual hospital screening and nutritional counseling on demand
Patients with acute Switzerland 132 leukemia			Standard nutritional care, including prescription of ONS on discretion of physician
⁴¹ Unwell elderly patients the 56 Netherlands	56		Free choice of normal hospital food and placebo 3 times daily (125 mL, 0 MJ/d)
² Older individuals with England 549 medical problems	549	eed supplement, 600 kcal/d, s daily, 19.6 g of fat daily, multivitamins	Normal hospital food plus 400 mL of oral sip-feed supplement, 600 kcal/d, Normal hospital food plus 400 mL of a placebo, 25.0 g of protein daily, 80.8 g of carbohydrates daily, plus multivitamins 100 kcal/d, 25 g of carbohydrates daily, plus multivitamin
Volkert et al, ⁴³ Hospitalized Germany 72 Normal hospital food a 1996 200 mL (1050 kJ) dail			Normal hospital food, usual care without supplements

ns

	Odds Ratio (95%	6 CI)	Risk Ratio (95% CI)	Mean Difference	e (95% CI)			
Variable	Mortality	Hospital- Acquired Infections	Nonelective Readmissions	Functional Outcome, Barthel Index Points	Length of Hospital Stay, d	Daily Caloric Intake, kcal	Daily Protein Intake, g	Weight Change, kg
Overall Population								
Intervention group, events/total (%)	133/1361 (9.8)	48/802 (6.0)	10/516 (20.5)	16.7	10.8	1662	54	0.83
Control group, events/total (%)	144/1395 (10.3)	63/812 (7.8)	14/497 (29.6)	16.7	13.0	1314	46	0.19
Overall estimate	0.96 (0.72 to 1.27)	0.75 (0.50 to 1.11)	0.71 (0.57 to 0.87)	0.33 (-0.88 to 1.55)	-0.42 (-1.09 to 0.24)	397 (279 to 515)	20.0 (12.5 to 27.1)	0.72 (0.23 to 1.21)
I ² Test for overall effect, %	49	0	0	85	0	89	91	92
Stratification by Malnu	utrition							
Established malnutrition	0.70 (0.43 to 1.13)	NA	0.45 (0.20 to 1.02)	4.00 (1.69 to 6.31)	-2.08 (-4.19 to 0.02)	354 (259 to 448)	18.9 (9.7 to 28.2)	1.22 (0.06 to 2.38)
Risk for malnutrition	1.14 (0.83 to 1.57)	0.75 (0.50 to 1.11)	0.73 (0.59 to 0.90)	-0.26 (-0.72 to 0.20)	-0.24 (-0.94 to 0.46)	434 (245 to 624)	17.8 (3.7 to 31.9)	0.80 (0.45 to 1.16)
I ² Test for subgroup difference, %	64	NA	21	92	49	0	0	0
Stratification by Morta	ality Risk in Contro	ol Group						
High mortality risk, ≥10%	0.77 (0.59 to 1.02)	0.77 (0.17 to 3.46)	NA	0.85 (-1.47 to 3.16)	-0.89 (-2.50 to 0.72)	231 (81 to 380)	16.0 (2.9 to 29.9)	0.41 (-0.42 to 1.24)
Low mortality risk, <10%	1.45 (0.99 to 2.13)	0.75 (0.50 to 1.13)	0.73 (0.59 to 0.90)	-0.30 (-0.86 to 0.26)	-0.15 (-0.91 to 0.61)	455 (321 to 587)	18.9 (11.5 to 26.4)	0.83 (0.47 to 1.19)
<i>I</i> ² Test for subgroup difference, %	86	0	NA	0	0	79	0	0
Stratification by Adhe	rence to Nutrition	Protocol						
High adherence	1.17 (0.69 to 1.99)	0.71 (0.41 to 1.24)	0.66 (0.43 to 1.01)	NA	-0.09 (-0.99 to 0.88)	430 (324 to 537)	20.0 (13.5 to 26.6)	0.90 (0.55 to 1.25)
Low adherence	0.78 (0.53 to 1.13)	0.79 (0.45 to 1.38)	0.72 (0.57 to 0.92)	0.33 (-0.88 to 1.55)	-0.82 (-1.80 to 0.16)	107 (24 to 191)	8.3 (-3.2 to 19.8)	0.17 (-0.51 to 0.84)
I ² Test for subgroup difference, %	35	35	0	NA	0	95	67	72
Stratification by Route	e of Nutritional The	erapy						
Oral feeding, noninterventional	0.97 (0.68 to 1.38)	0.75 (0.50 to 1.11)	0.73 (0.59 to 0.90)	0.33 (-0.88 to 1.55)	-0.29 (-0.97 to 0.40)	383 (261 to 505)	17.8 (10.9 to 24.8)	0.72 (0.23 to 1.21)
Enteral feeding	NA	NA	0.45 (0.2 to 1.02)	NA	-2.60 (-5.32 to 0.12)	613 (318 to 908)	48.6 (36.2 to 61.0)	NA
I ² Test for subgroup difference, %	NA	NA	21	NA	52	50	94	NA

Table 2. Outcomes Overall and in Subgroups

Abbreviation: NA, not applicable.

Body Weight and Nutritional Intake

Sixteen studies reported weight change from the time of randomization to the end of follow-up (until hospital discharge in most studies). Overall, weight increase was significantly higher in intervention group patients compared with control group patients (mean weight increase, 0.72 kg; 95% CI, 0.23-1.21 kg). This finding was true in most trials, although heterogeneity was high. Overall, daily caloric intake was significantly higher in intervention group patients compared with control group patients (difference, 397 kcal; 95% CI, 279-515 kcal). Similarly, daily protein intake was significantly higher in intervention group patients compared with control group patients (difference, 20.0 g/d; 95% CI, 12.5-27.1 g/d).

Sensitivity Analyses

In sensitivity analyses, we stratified trials by degree of malnutrition, control group mortality, adherence to nutrition protocols, and route of nutritional support (oral vs enteral feeding) (eAppendix in the Supplement). There were suggestions of larger benefits from nutritional therapy for the subgroup of patients with established malnutrition compared with patients at risk for malnutrition, particularly for mortality, functional outcome, and length of hospital stay. For patients having higher mortality risk (≥10%) compared with patients having lower mortality risk (≥10%), the effects tended to be larger, with no statistically significant results in subgroup difference tests. Stratification by protocol adherence found more daily caloric and protein intake, as well as more weight gain, in trials with high adherence, but clinical outcomes were similar compared with the overall analysis.

Discussion


The findings of this first comprehensive systematic review and meta-analysis to date focusing on the acutely ill medical in-

Figure 2. Forest Plot Comparing Nutritional Intervention vs Control for Mortality

	Nutrition Interven		Control		Odds Ratio M-H.		Favors	E Favors			
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)		Intervention		ι	Wei	ight, %
Oral feeding alone vs placebo											
Vlaming et al, ⁴² 2001	14	274	12	275	1.18 (0.54-2.60)		_			11.	.4
Hogarth et al, ²⁷ 1996	5	9	8	16	1.25 (0.24-6.44)				_	2.	.9
Broqvist et al, ²¹ 1994	1	9	1	12	1.38 (0.07-25.43)					0.	.9
Gariballa et al, ²⁴ 2006	32	222	19	223	1.81 (0.99-3.30)					18.	.0
Subtotal (95% CI)	52	514	40	526	1.52 (0.96-2.39)			\diamond		33.	.2
Heterogeneity: $\tau^2 = 0.00$; $\chi_3^2 = 0.$ Test for overall effect: $z = 1.80$ (=0%				0.01	0.1	1.0	10	 100	

	Nutrition Interven		Control		Odds Ratio M-H.		
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)		
Oral feeding alone vs usual care							
Bunout et al, ²² 1989	2	17	5	19	0.37 (0.06-2.25)		
Potter et al, ³⁴ 2001	21	186	33	195	0.62 (0.35-1.13)		
Munk et al, ³¹ 2014	1	40	1	41	1.03 (0.06-16.98)		
Subtotal (95% CI)	24	243	39	255	0.61 (0.35-1.05)		
Heterogeneity: $\tau^2 = 0.00$; $\chi^2_2 = 0$. Test for overall effect: $z = 1.79$ (=0%					

Odds Ratio M-H, Random (95% CI) Favors Favors



	Nutrition Interven		Control		Odds Ratio M-H.		F	avors Eavoi	<i>'</i> \$		
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)			ntion Contr			Weight, %
Oral feeding alone vs no support						_					
Volkert et al, ⁴³ 1996	4	35	8	37	0.47 (0.13-1.72)						4.5
Subtotal (95% CI)	4	35	8	37	0.47 (0.13-1.72)		<	\sim			4.5
Heterogeneity: not applicable Test for overall effect: z = 1.14 (P = .	25)					0.01	0.1	1.0	10	100	

Odds Ratio M-H, Random (95% CI)

	Nutrition Interven		Control		Odds Ratio M-H.	Favors	Favors	
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)	Intervention	Control	Weight, %
Oral feeding with dietary advice vs us	ual care							
Starke et al, ⁴⁰ 2011	2	66	5	66	0.38 (0.07-2.04)			2.8
Neelemaat et al, ³² 2012	11	105	14	105	0.76 (0.33-1.76)			10.2
Saudny-Unterberger et al, 38 1997	1	17	1	16	0.94 (0.05-16.37)			1.0
Holyday et al, ²⁸ 2012	4	71	1	72	4.24 (0.46-38.90)			1.6
Rüfenacht et al, ³⁶ 2010	4	18	1	18	4.86 (0.49-48.57)			1.5
Subtotal (95% CI)	22	277	22	277	1.05 (0.44-2.46)	<	>	17.1
Heterogeneity: $\tau^2 = 0.22$; $\chi_4^2 = 5.12$ (Test for overall effect: $z = 0.10$ ($P = .$		=22%				0.01 0.1 1. Odds Ratio M-H,		

	Nutritional Intervention Co				Odds Ratio M-H.	Favors 🗄 Favors	
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)	Intervention Control	Weight, %
Oral feeding with dietary advice vs r	10 support					-	
Hickson et al, ²⁶ 2004	31	292	35	300	0.90 (0.54-1.50)		23.0
Subtotal (95% CI)	31	292	35	300	0.90 (0.54-1.50)		23.0
Heterogeneity: not applicable Test for overall effect: <i>z</i> = 0.41 (<i>P</i>	=.68)						
Total (95% CI)	133	1361	144	1395	0.96 (0.72-1.27)	\diamond	100.0
Heterogeneity: $\tau^2 = 0.02$; $\chi^2_{13} = 14$. Test for overall effect: $z = 0.30$ (<i>P</i> Test for subgroup difference: $\chi^2_4 =$	=.76)					0.01 0.1 1.0 10 1 Odds Ratio M-H, Random (95% CI)	רי נ00

M-H indicates Mantel-Haenszel.

patient population with established malnutrition or at risk for malnutrition are 3-fold. First, 22 RCTs met our inclusion criteria. We found considerable heterogeneity across trials for the type of intervention and control group, as well as the clinical setting, and mostly low study quality, with often unclear risk of bias. Second, overall and in most individual trials, nutri-

jamainternalmedicine.com
juniumcentameeteene.com

Figure 3, Forest Plot Comparing Nutritional Intervention vs Control for Nonelective Readmissions

	Experim	ental	Control		Risk Ratio M-H,		Favors	Favors	
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)		Intervention	Control	Weight, %
Enteral nutrition with dietary advice	vs usual car	e							
Somanchi et al, ³⁹ 2011 ^a	8	106	14	83	0.45 (0.20-1.02)				6.5
Subtotal (95% CI)	8	106	14	83	0.45 (0.20-1.02)				6.5
Heterogeneity: not applicable Test for overall effect: z = 1.92 (P =	.05)					0.1	1. Risk Ratio M-H, F		
	Experim	ental	Control					_	
Study or Subgroup	Events	Total	Events	Total	Risk Ratio M-H, Random (95% CI)		Favors Intervention	Favors Control	Weight, %
Oral feeding alone vs placebo									
Gariballa et al, ²⁴ 2006	65	222	89	223	0.73 (0.57-0.95)		-		64.7
Vermeeren et al, ⁴¹ 2004	4	23	5	24	0.83 (0.26-2.73)				3.1
Subtotal (95% CI)	69	245	94	247	0.74 (0.57-0.95)		\diamond		67.9
Heterogeneity: $\tau^2 = 0.00$; $\chi_1^2 = 0.04$ Test for overall effect: $z = 2.34$ (P =	(P=.83); I ² .02)	=0%				0.1	1. Risk Ratio M-H, F		
	Experim	ental	Control		Risk Ratio M-H,		Favors	Favors	
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)		Intervention	Control	Weight, %
Oral feeding alone vs no support									
Gazzotti et al, ²⁵ 2003	4	34	3	35	1.37 (0.33-5.68)				2.2
Subtotal (95% CI)	4	34	3	35	1.37 (0.33-5.68)				2.2
Heterogeneity: not applicable Test for overall effect: z = 0.44 (P =	.66)					0.1	1. Risk Ratio M-H, F		
	Experim	ental	Control		Risk Ratio M-H,		Favors	Favors	
Study or Subgroup	Events	Total	Events	Total	Random (95% CI)		Intervention	Control	Weight, %
Oral feeding with dietary advice vs us	sual care								
Holyday et al, ²⁸ 2012 ^b	8	67	8	71	1.06 (0.42-2.66)				5.2
Starke et al, ⁴⁰ 2011	17	64	28	61	0.58 (0.35-0.94)				18.3
Subtotal (95% CI)	25	131	36	132	0.69 (0.40-1.18)		\sim	>	23.4
Heterogeneity: $\tau^2 = 0.04$; $\chi_1^2 = 1.31$ Test for overall effect: $z = 1.36$ ($P =$	(P=.25); I ² .17)	=24%							
Total (95% CI)	106	516	147	497	0.71 (0.57-0.87)		\diamond		100.0
Heterogeneity: $\tau^2 = 0.00$; $\chi = 3.57$ Test for overall effect: $z = 3.26$ ($P =$ Test for subgroup difference: $\chi_3^2 = 2$.001)					0.1	1. Risk Ratio M-H, F		

^a Calculated and approximated from readmission rate.

^b Calculated and approximated from readmission frequency.

tional support was significantly associated with higher daily caloric and protein intake, most likely explaining the detected mean weight gain difference of 0.72 kg compared with controls. Third, there was little effect on clinical outcomes overall, including mortality, hospital-acquired infections, and functional outcome. Still, in the overall analysis, nonelective readmissions were significantly lower among intervention group patients, suggesting that improved nutritional status might positively affect the recurrence of illnesses in medical patients after hospital discharge. The number needed to treat for readmission was 23 (95% CI, 16-52), assuming a readmission proportion of 15%.⁴⁴ Also, in the subgroup of patients with established malnutrition, the length of hospital stay tended to be shorter in the intervention group.

Nutritional support using oral nutrition (mainly via oral nutritional supplement) or enteral feeding is one of the most common interventions in medicine. Still, there is a lack of comprehensive trial data demonstrating its beneficial effects on outcomes in the general medical inpatient population. This paucity might explain why no standard nutritional algorithm for use in polymorbid medical inpatients with malnutrition or at risk for malnutrition exists today, to our knowledge. Most guidelines from the American Society for Parenteral and Enteral Nutrition and the European Society for Parenteral and Enteral Nutrition focus on specific medical disciplines (eg, individuals with cancer, geriatric patients, and those with sepsis) or organs (eg, renal failure and wound healing)⁴⁵⁻⁵⁶ but give little guidance on polymorbid patients. Also, current recommendations are mostly based on pathophysiological considerations and evidence from smaller trials. As a consequence, general internists caring for polymorbid inpatients may have insufficient evidence for informed decision making in individual patients for optimal use of nutritional therapy. In light of potential harmful effects of nutritional therapy, as demonstrated in the critical care patient population,⁴ a reappraisal of how nutritional therapy should be used in non-critically ill medical inpatients is required. Therefore, this systematic review and meta-analysis is important to give a comprehensive overview of the expected effects of different nutritional interventions on metabolic and clinical outcomes of medical inpatients. Our study differs from previous meta-analyses^{11,12} because we did not limit trials to specific interventions (eg, oral nutritional supplement only or enteral feeding) or patient populations. We focused on a broad medical inpatient population but excluded surgical and critical care patients, those with pancreatitis, and individuals with less acute disease residing in long-term facilities, where the effects of nutritional therapy may differ from the acute care setting.

Most important, data have suggested that nutritional therapy can also negatively affect clinical outcomes if used early in sick patients.^{8,57,58} During the acute phase of illness, the body mobilizes substrates from muscle and fat tissue to match increases in resting energy expenditure.⁵⁹ Exogenous calories then no longer inhibit gluconeogenesis. Therefore, excessive nutrition during the acute phase of illness can induce occult overfeeding and may interact with autophagy.3 However, other research demonstrated benefits from individually optimized energy supplementation with early parenteral feeding (3 days after admission) in severely ill patients in the intensive care unit for whom enteral nutrition alone was insufficient.⁶⁰ The contradictory findings from these critical care trials may be partly explained by the differences in time points when feeding was initiated. Our analysis found no evidence of harm associated with nutritional therapy in medical inpatients, which is reassuring. Yet, individual trials in our analysis were not powered for mortality, and trial quality was low, with often unclear risk of bias. Therefore, harmful effects cannot be excluded at this point, and larger conclusive trials are needed. Also, there is a lack of cost-benefit data for our patient population, and costs may still outweigh clinical benefits such as lower readmission rates.

Data from critical care cannot unconditionally be extrapolated to medical inpatients, who have a lower degree of disease severity. Still, the conflicting observations regarding the benefits of early nutritional support in critically ill patients begs an additional question and requires additional studies to better define the optimal approach in medical inpatients. As highlighted by this systematic search and meta-analysis, the current lack of guideline recommendations for nutritional support in general medical inpatients might be mainly explained by the paucity of high-quality studies providing evidence on the efficacy, safety, and cost-effectiveness of this strategy. Given the complex nature of nutritional therapy regarding the type of nutrition (eg, the amount and type of protein and the total amount of calories), method of delivery (oral vs enteral), timing, and adherence, a comprehensive effectiveness research trial that includes a large and diverse patient population is needed to demonstrate which patients benefit most from nutritional therapy. In light of the results of our subgroup analysis, patients with established malnutrition and higher-acuity patients may be more likely to have positive results. In a second step, trials investigating specific nutritional aspects are needed to delineate which nutritional components have positive influences on specific medical conditions (eg, immunonutrition).

Our study has several limitations. The included RCTs were mostly older studies randomizing small numbers of patients. There was considerable heterogeneity with respect to treatment modalities and patient populations as a result of using wide inclusion criteria and not limiting the trials to specific interventions or patient populations. Furthermore, according to the GRADE method, ¹⁸ the quality of the evidence was low to very low for most outcomes. Finally, the risk-of-bias analysis revealed unclear risks for most biases and high risk for performance bias and attrition bias. In addition, the wide 95% CIs for most patient-relevant clinical outcomes preclude any firm conclusions regarding the effects of nutritional support. Yet, our findings call for conducting more high-quality RCTs covering this important topic.⁶

Conclusions

For the medical inpatient population, our results show that nutritional interventions increase daily caloric and protein intake, as well as body weight. Yet, there is little effect of nutritional support on clinical outcomes in malnourished medical inpatients overall except for a significant reduction in nonelective admissions and a suggestion of shorter length of hospital stay. High-quality RCTs are needed to provide more definite conclusions.

ARTICLE INFORMATION

Accepted for Publication: September 25, 2015. Published Online: December 21, 2015.

doi:10.1001/jamainternmed.2015.6587.

Author Affiliations: University Department of Medicine, Clinic for Endocrinology/Metabolism/ Clinical Nutrition, Kantonsspital Aarau, Aarau, Switzerland (Bally, Bounoure, Mueller, Schuetz); Medical Faculty of the University of Basel, Basel, Switzerland (Bally, Bounoure, Mueller, Schuetz); General Medicine, Dr M. Deppeler, Zollikofen, Switzerland (Blaser Yildirim); Basel Institute for Clinical Epidemiology and Biostatistics, Department of Clinical Research, University Hospital Basel, Basel, Switzerland (Gloy, Briel); Institute of Nuclear Medicine, University Hospital Bern, Switzerland (Gloy); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (Briel).

Author Contributions: Drs Bally and Blaser Yildirim contributed equally to this work. Drs Briel and Schuetz had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. *Acquisition, analysis, or interpretation of data:* Bally, Blaser Yildirim, Bounoure. *Drafting of the manuscript:* All authors. *Critical revision of the manuscript for important intellectual content:* All authors. *Statistical analysis:* Bally, Bounoure, Gloy, Briel, Schuetz.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported in part by grant PPOOP3_150531/1 from the Swiss National Science Foundation and by grant 1410.000.044 from the Research Council of the Kantonsspital Aarau.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: Heidrun Janka, PhD (Universitätsbibliothek Medizin, Basel, Switzerland) and the Cochrane Metabolic and Endocrine Disorders Group assisted with the literature search.

REFERENCES

1. Kubrak C, Jensen L. Malnutrition in acute care patients: a narrative review. *Int J Nurs Stud*. 2007; 44(6):1036-1054.

2. Schütz P, Bally M, Stanga Z, Keller U. Loss of appetite in acutely ill medical inpatients: physiological response or therapeutic target? *Swiss Med Wkly*. 2014;144:w13957.

3. Casaer MP, Hermans G, Wilmer A, Van den Berghe G. Impact of Early Parenteral Nutrition Completing Enteral Nutrition in Adult Critically III Patients (EPaNIC trial): a study protocol and statistical analysis plan for a randomized controlled trial. *Trials*. 2011;12:21.

4. Villet S, Chiolero RL, Bollmann MD, et al. Negative impact of hypocaloric feeding and energy balance on clinical outcome in ICU patients. *Clin Nutr*. 2005;24(4):502-509.

5. Felder S, Lechtenboehmer C, Bally M, et al. Association of nutritional risk and adverse medical outcomes across different medical inpatient populations. *Nutrition*. 2015;31(11-12):1385-1393.

6. Schuetz P. "Eat your lunch!" controversies in the nutrition of the acutely, non-critically ill medical inpatient. *Swiss Med Wkly*. 2015;145:w14132.

7. Casaer MP, Van den Berghe G. Nutrition in the acute phase of critical illness. *N Engl J Med*. 2014; 370(25):2450-2451.

8. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. *N Engl J Med*. 2011;365(6):506-517.

9. Arabi YM, Aldawood AS, Haddad SH, et al; PermiT Trial Group. Permissive underfeeding or standard enteral feeding in critically ill adults [published correction appears in *N Engl J Med*. 2015;373(13):1281]. *N Engl J Med*. 2015;372(25): 2398-2408.

10. Doig GS, Simpson F, Sweetman EA, et al; Early PN Investigators of the ANZICS Clinical Trials Group. Early parenteral nutrition in critically ill patients with short-term relative contraindications to early enteral nutrition: a randomized controlled trial. *JAMA*. 2013;309(20):2130-2138.

11. Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? a systematic review of the randomized trials. *Am J Gastroenterol*. 2007;102(2):412-429.

 Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. *Cochrane Database Syst Rev*. 2009;(2):CD003288.

13. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. *Cochrane Database Syst Rev.* 2012;5:CD008344.

14. Avenell A, Handoll HH. Nutritional supplementation for hip fracture aftercare in older people. *Cochrane Database Syst Rev.* 2010;(1): CD001880.

15. Schuetz P, Blaser Yildirim PZ, Gloy VL, Briel M, Bally MR. Early nutritional therapy for malnourished or nutritionally at-risk adult medical inpatients (Protocol). *Cochrane Database Syst Rev*. 2014;(5): CD011096. doi:10.1002/14651858.CD011096.

16. Gianotti L, Meier R, Lobo DN, et al; ESPEN. ESPEN Guidelines on Parenteral Nutrition: pancreas. *Clin Nutr*. 2009;28(4):428-435.

17. Higgins JP, Altman DG, Gøtzsche PC, et al; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928.

18. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336(7650):924-926.

19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557-560.

20. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. *J Clin Epidemiol*. 2001;54(10):1046-1055.

21. Broqvist M, Arnqvist H, Dahlström U, Larsson J, Nylander E, Permert J. Nutritional assessment and muscle energy metabolism in severe chronic congestive heart failure: effects of long-term dietary supplementation. *Eur Heart J.* 1994;15(12): 1641-1650.

22. Bunout D, Aicardi V, Hirsch S, et al. Nutritional support in hospitalized patients with alcoholic liver disease. *Eur J Clin Nutr.* 1989;43(9):615-621.

23. Feldblum I, German L, Castel H, Harman-Boehm I, Shahar DR. Individualized nutritional intervention during and after hospitalization: the nutrition intervention study clinical trial. *J Am Geriatr Soc.* 2011;59(1):10-17.

24. Gariballa S, Forster S, Walters S, Powers H. A randomized, double-blind, placebo-controlled trial of nutritional supplementation during acute illness. *Am J Med*. 2006;119(8):693-699.

25. Gazzotti C, Arnaud-Battandier F, Parello M, et al. Prevention of malnutrition in older people during and after hospitalisation: results from a randomised controlled clinical trial. *Age Ageing*. 2003;32(3):321-325.

26. Hickson M, Bulpitt C, Nunes M, et al. Does additional feeding support provided by health care assistants improve nutritional status and outcome in acutely ill older in-patients? a randomised control trial. *Clin Nutr.* 2004;23(1):69-77.

27. Hogarth MB, Marshall P, Lovat LB, et al. Nutritional supplementation in elderly medical in-patients: a double-blind placebo-controlled trial. *Age Ageing*. 1996;25(6):453-457.

28. Holyday M, Daniells S, Bare M, Caplan GA, Petocz P, Bolin T. Malnutrition screening and early nutrition intervention in hospitalised patients in acute aged care: a randomised controlled trial. *J Nutr Health Aging*. 2012;16(6):562-568.

29. McEvoy AW, James OF. The effect of a dietary supplement (Build-up) on nutritional status in hospitalized elderly patients. *Hum Nutr Appl Nutr.* 1982;36(5):374-376.

30. McWhirter JP, Pennington CR. A comparison between oral and nasogastric nutritional supplements in malnourished patients. *Nutrition*. 1996;12(7-8):502-506.

31. Munk T, Beck AM, Holst M, et al. Positive effect of protein-supplemented hospital food on protein intake in patients at nutritional risk: a randomised controlled trial. *J Hum Nutr Diet*. 2014;27(2):122-132.

32. Neelemaat F, Lips P, Bosmans JE, Thijs A, Seidell JC, van Bokhorst-de van der Schueren MA. Short-term oral nutritional intervention with protein and vitamin D decreases falls in malnourished older adults. *J Am Geriatr Soc.* 2012; 60(4):691-699. **33**. Ollenschläger G, Thomas W, Konkol K, Diehl V, Roth E. Nutritional behaviour and quality of life during oncological polychemotherapy: results of a prospective study on the efficacy of oral nutrition therapy in patients with acute leukaemia. *Eur J Clin Invest.* 1992;22(8):546-553.

34. Potter JM, Roberts MA, McColl JH, Reilly JJ. Protein energy supplements in unwell elderly patients: a randomized controlled trial. *JPEN J Parenter Enteral Nutr*. 2001;25(6):323-329.

35. Roberts M, Potter J, McColl J, Reilly J. Can prescription of sip-feed supplements increase energy intake in hospitalised older people with medical problems? *Br J Nutr.* 2003;90(2):425-429.

36. Rüfenacht U, Rühlin M, Wegmann M, Imoberdorf R, Ballmer PE. Nutritional counseling improves quality of life and nutrient intake in hospitalized undernourished patients. *Nutrition*. 2010;26(1):53-60.

37. Ryan M, Salle A, Favreau AM, et al. Oral supplements differing in fat and carbohydrate content: effect on the appetite and food intake of undernourished elderly patients. *Clin Nutr*. 2004; 23(4):683-689.

38. Saudny-Unterberger H, Martin JG, Gray-Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 1997;156(3, pt 1):794-799.

39. Somanchi M, Tao X, Mullin GE. The facilitated early enteral and dietary management effectiveness trial in hospitalized patients with malnutrition. *JPEN J Parenter Enteral Nutr.* 2011;35 (2):209-216.

40. Starke J, Schneider H, Alteheld B, Stehle P, Meier R. Short-term individual nutritional care as part of routine clinical setting improves outcome and quality of life in malnourished medical patients. *Clin Nutr.* 2011;30(2):194-201.

41. Vermeeren MA, Wouters EF, Geraerts-Keeris AJ, Schols AM. Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. *Clin Nutr*. 2004;23(5):1184-1192.

42. Vlaming S, Biehler A, Hennessey EM, et al. Should the food intake of patients admitted to acute hospital services be routinely supplemented? a randomized placebo controlled trial. *Clin Nutr.* 2001;20(6):517-526.

43. Volkert D, Hübsch S, Oster P, Schlierf G. Nutritional support and functional status in undernourished geriatric patients during hospitalization and 6-month follow-up. *Aging* (*Milano*). 1996;8(6):386-395.

44. Kaboli PJ, Go JT, Hockenberry J, et al. Associations between reduced hospital length of stay and 30-day readmission rate and mortality: 14-year experience in 129 Veterans Affairs hospitals. *Ann Intern Med*. 2012;157(12):837-845.

45. Arends J, Bodoky G, Bozzetti F, et al; DGEM (German Society for Nutritional Medicine); ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: non-surgical oncology. *Clin Nutr*. 2006;25(2): 245-259.

46. August DA, Huhmann MB; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines:

E10 JAMA Internal Medicine Published online December 21, 2015

nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. *JPEN J Parenter Enteral Nutr.* 2009;33(5):472-500.

47. Brown RO, Compher C; American Society for Parenteral and Enteral Nutrition Board of Directors. A.S.P.E.N. clinical guidelines: nutrition support in adult acute and chronic renal failure. *JPEN J Parenter Enteral Nutr.* 2010;34(4):366-377.

48. Cano NJ, Aparicio M, Brunori G, et al; ESPEN. ESPEN Guidelines on Parenteral Nutrition: adult renal failure. *Clin Nutr*. 2009;28(4):401-414.

49. Choban P, Dickerson R, Malone A, Worthington P, Compher C; American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. clinical guidelines: nutrition support of hospitalized adult patients with obesity. *JPEN J Parenter Enteral Nutr.* 2013;37(6): 714-744.

50. McMahon MM, Nystrom E, Braunschweig C, Miles J, Compher C; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors; American Society for Parenteral and Enteral Nutrition. A.S.P.E.N. clinical guidelines: nutrition support of adult patients with hyperglycemia. *JPEN J Parenter Enteral Nutr*. 2013; 37(1):23-36. **51**. Mueller C, Compher C, Ellen DM; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: nutrition screening, assessment, and intervention in adults. *JPEN J Parenter Enteral Nutr.* 2011;35(1):16-24.

52. Plauth M, Cabré E, Riggio O, et al; DGEM (German Society for Nutritional Medicine); ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: liver disease. *Clin Nutr.* 2006;25(2):285-294.

53. Sobotka L, Schneider SM, Berner YN, et al; ESPEN. ESPEN Guidelines on Parenteral Nutrition: geriatrics. *Clin Nutr.* 2009;28(4):461-466.

54. Vanek VW, Borum P, Buchman A, et al; Novel Nutrient Task Force, Parenteral Multi-Vitamin and Multi-Trace Element Working Group; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. position paper: recommendations for changes in commercially available parenteral multivitamin and multi-trace element products [published correction appears in *Nutr Clin Pract*. 2014;29(5):701]. *Nutr Clin Pract*. 2012;27(4):440-491.

55. Vanek VW, Matarese LE, Robinson M, Sacks GS, Young LS, Kochevar M; Novel Nutrient Task Force, Parenteral Glutamine Workgroup; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. position paper: parenteral nutrition glutamine supplementation. *Nutr Clin Pract*. 2011;26(4):479-494.

56. Volkert D, Berner YN, Berry E, et al; DGEM (German Society for Nutritional Medicine); ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: geriatrics. *Clin Nutr.* 2006;25(2):330-360.

57. Heyland D, Muscedere J, Wischmeyer PE, et al; Canadian Critical Care Trials Group. A randomized trial of glutamine and antioxidants in critically ill patients [published correction appears in *N Engl J Med.* 2013;368(19):1853]. *N Engl J Med.* 2013;368 (16):1489-1497.

58. Schetz M, Casaer MP, Van den Berghe G. Does artificial nutrition improve outcome of critical illness? *Crit Care*. 2013;17(1):302.

59. Vincent JL, Preiser JC. When should we add parenteral to enteral nutrition? *Lancet*. 2013;381 (9864):354-355.

60. Heidegger CP, Berger MM, Graf S, et al. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. *Lancet*. 2013;381(9864):385-393.

Invited Commentary

Nutritional Support on the Medical Wards—Thought for Food

Jonathan P. Kushner, MD; Joseph A. Lacy, RD; Steven R Gay, MD

Malnutrition lurks in the background, if not the forefront, of hospitalized patients. More than one-third of patients are seen in the hospital with varying degrees of malnutrition,¹ and far

←

Related article

too many experience further nutritional deterioration during their stay and convalescence. We have become more

alert to this challenge ever since the shocking revelations in 1974 by Butterworth² that the issue of nutrition of inpatients was frequently neglected. Well before that, suboptimal nutrition states were closely associated with poor outcomes.³ However, 40 years after our eyes were opened to this longignored issue, we struggle to identify appropriate patients and efficacious nutritional interventions.

Malnutrition has been defined as a subacute or chronic state of nutrition in which a combination of varying degrees of overnutrition or undernutrition and inflammatory activity have led to deleterious changes in body composition and diminished function. While early and mild effects on appetite, intake, and metabolism are beneficial physiological responses in a host undergoing an inflammatory challenge, prolongation of these effects can eventually lead to impaired defenses and function, with worse outcomes. Nutritional interventions have the potential to offset some of the excessive losses and deficiencies but can also result in undesired consequences if delivered at the wrong time, in the wrong form, or by the wrong way. Nowhere has this dilemma been more clearly demonstrated than in critical care populations receiving overzealous deliveries of glucose, fat, and other nutrients via the parenteral route, resulting in hyperglycemia, immunosuppression, and negative outcomes.⁴ Most of our current knowledge and subsequent recommendations for nutritional intervention have come from studies of critical care or surgical populations, among whom time points, interventions, and end points can be more clearly defined and controlled. There is still controversy as to the optimal timing, route, and composition of nutritional interventions. Less well delineated are outcomes and recommendations for polymorbid hospitalized general medical patients. These patients often are seen with varying degrees of chronic malnutrition exacerbated by acute or chronic medical illness, and they may have coexisting conditions, each presenting challenges to the nutritional and metabolic milieu. As in other clinical settings, malnutrition and ongoing suboptimal food intake have been associated with failure to thrive, higher rates of infection, and greater hospital length of stay, readmission, and mortality, as well as increased health care costs. Welldesigned intervention studies with clear outcomes in this population are more challenging, making guidelines difficult to design.

In this issue of *JAMA Internal Medicine*, Bally and colleagues⁵ present an appropriately conducted metaanalysis of trials addressing nutritional intervention in malnourished medical inpatients. They analyzed 22 randomized clinical trials of more than 3700 patients that looked primar-

ily at polymorbid medical inpatients between 1989 and 2014. High heterogeneity across the studies was seen, as well as some unknown biases. As expected, nutritional intervention groups (mostly oral supplements or counseling, with fewer receiving enteral tube feeding) had greater intake and weight gain than control arms, but the primary outcome of mortality and important secondary outcomes of infections, physical function, or hospital length of stay were not aided by nutritional intervention. There was a trend to a shorter length of stay in a subgroup of already malnourished patients. Nonelective readmissions in the intervention groups were statistically less, with a number needed to treat of 23. Overall, even with the potential for publication and attrition bias, the benefits of nutritional intervention in this population appear to be modest. However, while the hospital readmission rate was not the primary outcome of this meta-analysis, the improvement seen presents a potentially important piece of evidence to support nutritional intervention in light of rising health care costs in the 21st century. To date, there have been limited costeffective analyses of nutritional intervention in medical inpatients,⁶ perhaps a topic in need of further investigation.

Earlier, Potter et al⁷ examined 30 randomized trials of routine oral or enteral protein supplementation in a metaanalysis of more than 2000 adults. They found improved nutritional indexes but an uncertain trend to reduced mortality, hampered by publication bias and trial methods. The population was composed of both healthy elderly outpatients and a mix of surgical and medical inpatients using predominantly oral supplementation. Subgroup analysis showed a less impressive mortality benefit for supplementation in medical patients. The large Cochrane Collaboration meta-analysis by Milne et al⁸ examined oral nutritional supplementation in more than 10 000 elderly patients in 62 trials. The majority were hospitalized patients. Again, nutritional status improved with intervention, but other beneficial outcomes were not demonstrated because of problems with study methods and quality. Reduced mortality in the already malnourished subgroup was suggested. Inadequate duration of supplementation was cited as a potential drawback. A large systematic review of randomized trials of oral or tube-fed supplementation by Koretz et al⁹ found benefits with oral supplementation only in the already malnourished elderly among medical patients.

Joint Commission on Accreditation of Healthcare Organizations regulations have prompted more rigorous nutritional screening in hospitalized patients.¹⁰ In turn, a number of organizations have promulgated pathways and guidelines not only for screening and assessment of all hospitalized patients but also for nutritional intervention. However, the recommendations outside of the critical care or perioperative arena in many cases are based on low levels of evidence, derived from trials that fail to provide clear-cut evidence of beneficial and cost-effective nutritional intervention.

jamainternalmedicine.com

Several challenges remain. Our present-day practices may result in mishandling the delicate balance of nutritional, metabolic, and immune system function, to our patients' detriment. Current composition and timing of nutritional therapy may be suboptimal. Oral supplements and some tube feedings contain significant amounts of sugar, corn syrup solids, and maltodextrin, which may affect glycemic index and other responses. Continuous tube feeding and parenteral nutrition may potentially desynchronize a range of anabolic metabolic processes. The relationships among nutrition, activity, and physical therapy to optimize nutrient and growth effect may be underappreciated. Medical inpatients represent a diverse group with complicated needs, and it may not be possible to make broad recommendations across this population. We should continue to strive for high-quality randomized studies that more clearly delineate appropriate target populations for nutritional intervention and, with that, the specific route, type, and amount of nutrition that results in the best outcome. Even for the less invasive and less expensive option of dietary counseling and oral supplements, we must be sure that these methods also avoid unwanted negative effects and meet cost-effective standards. The exciting challenge of defining optimal nutritional interventions for specific situations continues.

ARTICLE INFORMATION

Author Affiliations: Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio (Kushner, Gay); Division of Trauma and Critical Care, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio (Lacy).

Corresponding Author: Jonathan P. Kushner, MD, Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine; 231 Albert Sabin Way, Cincinnati, OH 45267-0595 (jonathan.kushner@uc.edu).

Published Online: December 21, 2015. doi:10.1001/jamainternmed.2015.7062.

Conflict of Interest Disclosures: None reported.

REFERENCES

1. Hulsewé KW, van Acker BA, von Meyenfeldt MF, Soeters PB. Nutritional depletion and dietary manipulation: effects on the immune response. *World J Surg.* 1999;23(6):536-544. **2**. Butterworth C. The skeleton in the hospital closet. *Nutr Today*. 1974;9(2):4-8.

3. Parekh NR, Steiger E. Percentage of weight loss as a predictor of surgical risk: from the time of Hiram Studley to today. *Nutr Clin Pract*. 2004;19(5): 471-476.

4. Casaer MP, Mesotten D, Hermans G, et al. Early versus late parenteral nutrition in critically ill adults. *N Engl J Med.* 2011;365(6):506-517.

 Bally MR, Blaser Yildirim PZ, Bounoure L, et al. Nutritional support and outcomes in malnourished medical inpatients: a systematic review and meta-analysis [published online December 21, 2015]. JAMA Intern Med. doi:10.1001 /jamainternmed.2015.6587.

6. Elia M, Normand C, Laviano A, Norman K. A systematic review of the cost and cost effectiveness of using standard oral nutritional supplements in community and care home settings. *Clin Nutr.* 2015;S0261-5614(15)00191-0. doi:10.1016/j.clnu.2015.07.012.

7. Potter J, Langhorne P, Roberts M. Routine protein energy supplementation in adults: systematic review. *BMJ*. 1998;317(7157):495-501.

8. Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. *Cochrane Database Syst Rev.* 2009;(2):CD003288.

9. Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? a systematic review of the randomized trials. *Am J Gastroenterol*. 2007;102(2):412-429.

10. Mueller C, Compher C, Ellen DM; American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and intervention in adults. *JPEN J Parenter Enteral Nutr*. 2011;35(1):16-24.